XML 161 R78.htm IDEA: XBRL DOCUMENT v3.20.4
Segmentation of key figures (Details 2) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disclosure of operating segments [line items]      
Interest income $ 91 $ 245 $ 292
Impairment charges and fair value gains on financial assets, net 335 38 (6)
Additions to restructuring provisions (354) (492) (521)
Continuing operations      
Disclosure of operating segments [line items]      
Equity-based compensation of Novartis equity plans (958) (1,067) (918)
Property, plant and equipment [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (1,318) (1,345) (1,482)
Impairment loss (reversal of impairment loss) recognised in profit or loss (440) (202) (301)
Right-of-use assets [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (330) (305)  
Intangible assets and goodwill [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (3,462) (2,836) (2,587)
Impairment loss (reversal of impairment loss) recognised in profit or loss (914) (1,138) (841)
Operating segments [member] | Innovative Medicines | Continuing operations      
Disclosure of operating segments [line items]      
Impairment charges and fair value gains on financial assets, net 153 18 107
Additions to restructuring provisions (217) (229) (395)
Equity-based compensation of Novartis equity plans (714) (761) (645)
Operating segments [member] | Innovative Medicines | Property, plant and equipment [member] | Continuing operations      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (912) (952) (1,075)
Impairment loss (reversal of impairment loss) recognised in profit or loss (324) (100) (239)
Operating segments [member] | Innovative Medicines | Right-of-use assets [member] | Continuing operations      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (273) (247)  
Operating segments [member] | Innovative Medicines | Intangible assets and goodwill [member] | Continuing operations      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (3,080) (2,509) (2,214)
Impairment loss (reversal of impairment loss) recognised in profit or loss (768) (632) (592)
Operating segments [member] | Sandoz | Continuing operations      
Disclosure of operating segments [line items]      
Additions to restructuring provisions (98) (165) (32)
Equity-based compensation of Novartis equity plans (64) (67) (53)
Operating segments [member] | Sandoz | Property, plant and equipment [member] | Continuing operations      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (282) (283) (285)
Impairment loss (reversal of impairment loss) recognised in profit or loss (116) (101) (60)
Operating segments [member] | Sandoz | Right-of-use assets [member] | Continuing operations      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (41) (41)  
Operating segments [member] | Sandoz | Intangible assets and goodwill [member] | Continuing operations      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (370) (315) (366)
Impairment loss (reversal of impairment loss) recognised in profit or loss (141) (506) (249)
Operating segments [member] | Corporate | Continuing operations      
Disclosure of operating segments [line items]      
Impairment charges and fair value gains on financial assets, net 182 20 (113)
Additions to restructuring provisions (39) (98) (94)
Equity-based compensation of Novartis equity plans (180) (239) (220)
Operating segments [member] | Corporate | Property, plant and equipment [member] | Continuing operations      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (124) (110) (122)
Impairment loss (reversal of impairment loss) recognised in profit or loss   (1) (2)
Operating segments [member] | Corporate | Right-of-use assets [member] | Continuing operations      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (16) (17)  
Operating segments [member] | Corporate | Intangible assets and goodwill [member] | Continuing operations      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (12) $ (12) $ (7)
Impairment loss (reversal of impairment loss) recognised in profit or loss $ (5)